Viridian Therapeutics Valuation
| VRDN Stock | USD 19.03 0.00 0.00% |
At this time, the company appears to be undervalued. Viridian Therapeutics has a current Real Value of $24.39 per share. The regular price of the company is $19.03. Our model measures the value of Viridian Therapeutics from inspecting the company fundamentals such as Shares Owned By Institutions of 100.00 %, return on equity of -0.52, and Current Valuation of 964.97 M as well as reviewing its technical indicators and probability of bankruptcy.
Price Book 2.9082 | Enterprise Value 965 M | Enterprise Value Ebitda (3.18) | Price Sales 5 K | Enterprise Value Revenue 3.2 K |
Undervalued
Today
Please note that Viridian Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Viridian Therapeutics is based on 3 months time horizon. Increasing Viridian Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Viridian Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Viridian Stock. However, Viridian Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.03 | Real 24.39 | Target 43.53 | Hype 19.04 |
The intrinsic value of Viridian Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Viridian Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Viridian Therapeutics helps investors to forecast how Viridian stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Viridian Therapeutics more accurately as focusing exclusively on Viridian Therapeutics' fundamentals will not take into account other important factors: Viridian Therapeutics Total Value Analysis
Viridian Therapeutics is at this time forecasted to have valuation of 964.97 M with market capitalization of 1.51 B, debt of 21.05 M, and cash on hands of 161.21 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Viridian Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
964.97 M | 1.51 B | 21.05 M | 161.21 M |
Viridian Therapeutics Investor Information
About 100.0% of the company outstanding shares are owned by institutional investors. The book value of Viridian Therapeutics was at this time reported as 6.55. The company recorded a loss per share of 4.32. Viridian Therapeutics last dividend was issued on the 13th of November 2020. The entity had 1:15 split on the 13th of November 2020. Based on the key indicators related to Viridian Therapeutics' liquidity, profitability, solvency, and operating efficiency, Viridian Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Viridian Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Viridian Therapeutics has an asset utilization ratio of 0.064 percent. This suggests that the Company is making $6.4E-4 for each dollar of assets. An increasing asset utilization means that Viridian Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Viridian Therapeutics Ownership Allocation
The majority of Viridian Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Viridian Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Viridian Therapeutics. Please pay attention to any change in the institutional holdings of Viridian Therapeutics as this could imply that something significant has changed or is about to change at the company.Viridian Therapeutics Profitability Analysis
The company reported the previous year's revenue of 314 K. Net Loss for the year was (237.73 M) with loss before overhead, payroll, taxes, and interest of (99.12 M).About Viridian Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Viridian Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Viridian Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Viridian Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Viridian Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Viridian Therapeutics. We calculate exposure to Viridian Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Viridian Therapeutics's related companies.Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts. Viridian Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 50 people.
Viridian Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 44.8 M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 0.005 | Quarterly Revenue Growth 0.194 | Return On Assets (0.32) | Return On Equity (0.52) |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.